U.S. Contraceptive Drugs and Devices Market is anticipated to surpass 11,770.0 Mn in 2026, Driven by Rising Demand for Effective Family Planning Solutions

The U.S. Contraceptive Drugs and Devices Market, estimated at USD 11,770.0 Mn in 2026, is expected to exhibit a CAGR of 5.6% and reach USD 17,330.9 Mn by 2033.

The U.S. Contraceptive Drugs and Devices Market was valued at USD 11,770.0 Million in 2026 and is projected to expand at a CAGR of 5.6% during the forecast period (2026–2033). Patent expiries to pave way for generics in the U.S. oral contraceptives market during the forecast period. Oral pills are the next preferred method of contraception after sterilization in the U.S. Therefore, we observe many combination and progestin only pills being available in the U.S. contraceptive drugs and devices market. Many generic companies are working on development of alternatives for major contraceptive pills that are projected to lose patent protection in the near future. To add to the projected wave of generic oral contraceptive pills, big pharma is interested more in selling pills which are revenue churning products rather than one-time long-acting contraceptive devices. This is expected to change the overall dynamics of the market. However, preference for long term contraception methods such as the IUD and implants are now increasing in the U.S. Safety issues have averted females from using these long-acting contraceptive methods until now. Improving IUD quality and implant devices with better safety measures is convincing females for adopting these methods now.

To know the latest trends and insights prevalent in the U.S. contraceptive drugs and devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-contraceptives-drugs-and-devices-market-368

The U.S. contraceptive drugs and devices market is expected to witness significant growth in the near future, owing to the development and launch of new generic products driven by the expiry of patents over the forecast period. Brands such as Femcon-FE, Lo Minastrin Fe, Taytulla, Minastrin 24 Fe, Yaz/Yasmin, Ortho Tri-Cyclen Lo, and Depo-subQ Provera—categorized under contraceptive drugs segment—are due for patent expiry during 2019-2021. Similarly, few contraceptive devices in the IUD and vaginal ring segments, are due for patent expiry during the forecast period, which in turn, is expected to increase the demand for generic brands in the U.S. contraceptive drugs and devices market. Rampant research for the development and commercialization of male contraceptive products is expected to fuel growth of the U.S. contraceptive drugs and devices market. Vasalgel—a long acting non-hormonal contraceptive—is one such male contraceptive product, funded by the Parsemus Foundation, successfully cleared pre-clinical studies and is expected to enter clinical trials in the near future. In the U.S., contraceptives are covered under the commercial health insurance policies through Affordable Care Act (ACA). This has significantly helps reduce out-of-pocket expenses on oral contraceptive pills from 21.8% in 2011 to 3.6% in 2014.

The U.S. has implemented coverage policy for contraceptives and all essential abortion related services without any co-pays, co-insurance or deductibles. This is a relief for the U.S. population relying on various contraceptive methods and increases adoption of expensive long-acting contraceptives. These factors in turn, are responsible for the U.S. contraceptive drugs and devices market growth. Additionally, increasing government subsidies and initiatives by non-profit organizations is contributing towards a sustainable market growth. The U.S. FDA approved Liletta, a hormonal IUD, is also promoted by Women’s Health Alliance, an organization engaged in promoting high-quality affordable healthcare for women, making it affordable or even free to women in low-income areas.

Key takeaways of the market

• Patent expirations in the near future, is expected to spur the entry of generics in the oral contraceptive pills, injectables, and IUD segments
• Launch of Twirla, a contraceptive patch, would be a threat for oral pills owing to convenience of drug administration through transdermal route.
• Based on the number of potential users of contraceptives, there is still a huge untapped market which manufacturers need to address through creating awareness and increasing market access
• The availability of contraceptive drugs and devices through online channels, has eased the purchase and increased reach of contraceptive products in the U.S. contraceptive drugs and devices market
• Sales through doctor channel is essential to be focused upon for modern contraceptive methods

Key News

• In June 2026, Organon completed a global licensing agreement with Sebela Pharmaceuticals for MIUDELLA, a hormone-free copper intrauterine device, strengthening its women’s health and contraception portfolio. Approved by the U.S. FDA in February 2025, MIUDELLA is the first hormone-free copper IUD introduced in the U.S. in over 40 years. The device prevents pregnancy for up to three years, is 99% effective, and is expected to launch commercially in late 2026 across clinical settings. (Source: Organon)
• In May 2026, Daré Bioscience, pharmaceutical company announced positive interim Phase 3 safety and efficacy results for Ovaprene, its investigational monthly, hormone-free intravaginal contraceptive. The independent DSMB recommended the study continue without modification, with no new tolerability concerns or device-related serious adverse events observed. Daré said Ovaprene could become the first FDA-approved hormone-free monthly intravaginal contraceptive in the U.S., addressing unmet demand for non-hormonal birth control options among women seeking alternatives. (Source: Daré Bioscience)